HIV / AIDS

The bold promise in last week’s State of the Union address is achievable, but may mean keeping the Affordable Care Act.

National Black HIV/AIDS Awareness Day is all about fighting the HIV stigma and encouraging education, testing, and prevention.

In an ongoing study spanning more than 15 years, investigators have made key discoveries about how HIV and TB drugs affect pregnant and postpartum women, leading to new safety and dosing recommendations for several medications.

In theory, investigators now have the tools to edit a patient’s genes to fight HIV. However, there’s a big difference between potential and reality.

The sNDAs will seek approval for the use of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate in individuals with HIV-1 whose virus is suppressed and are switching from a stable antiretroviral regimen.

A new review shows transgender women face higher HIV rates than transgender men, but also finds a relative lack of data about transmen.

In a new study, Michigan State University investigators identified an immune receptor, SLAMF7, that had the ability to decrease immune response when activated on monocytes.

New evidence suggests that use of certain opioids may increase the risk of developing pneumonia, particularly in patients with HIV.

Investigators in Canada link larger HIV reservoir sizes to a virus gene that is more functional in one subtype of the virus, with findings which may one day contribute to the development of an HIV cure.

Even when men who have sex with men are aware of the risk of hepatitis C infection, they aren’t always confident in their ability to go against the expectations of their peer group.

Despite promising early results, dolutegravir monotherapy should no longer be used as HIV maintenance therapy, a new study concludes.

People living with HIV are twice as likely to develop cardiovascular disease than noninfected individuals, and are more likely to have incident heart failure than the general population, even after adjustment for demographics and cardiovascular risk factors.

Single-tablet regimens may provide better virologic response and control than multiple-tablet regimens for people living with HIV, likely due to a lower pill burden and, subsequently, better medication adherence, according to the results of a new study.

Contagion® counts down the top HIV news stories of 2018, including FDA approvals, breakthrough studies, recommendations from the frontlines, and a big-picture look at just how close we are to a cure.

A smartphone app could be the critical link between at-home HIV testing and rapid access to care for people whose tests come back positive.

This orphan drug is for patients with limited antiretroviral treatment options.

Investigators have found that the parasitic infection schistosomiasis is associated with increased risk of HIV transmission, more advanced HIV stage, and a higher risk of death.

New research suggests liver macrophages should not be considered an HIV reservoir, and thus should not be considered a target for HIV therapies.

On December 1, 2018, international health organizations reflected on the advancements of the HIV/AIDS research field and acknowledged the challenges that still remain such as treating comorbidities and confronting stigma.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Could pharmacist-led medication reconciliation improve inpatient continuity of care in individuals with HIV?

Scientists think they’ve hit on the mechanism by which certain patients are able to keep their levels of HIV low without relying on medication.

A new report from the ECDC and WHO shows the disparity of new HIV diagnoses across Europe, with more than 80% of new cases occurring in Eastern Europe in 2017.

People living with HIV should get a flu shot each year, according to experts.

Draft guidance effectively outlines what infectious disease specialists have known for years—and leaves many unanswered questions.

Why take 3 drugs when you can keep your viral load at bay with just 2? A new study confirms that the dolutegravir/lamivudine pairing is non-inferior to a 3-drug regimen and may offer fewer toxic side effects.

People who inject drugs who are infected with hepatitis C virus can achieve sustained viral response, despite imperfect adherence, according to the results of a new trial.

As resistance, and incidence, are both on the rise, new options may come not a moment too soon.

A new study found that poor sleep quality, poor sleep duration, problems falling asleep, and problems staying awake during wake-time activities were associated with risky sexual behavior.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.